Skip to main content
TipRanks
Go Ultimate75% OFF

Intellia Therapeutics (38I) Stock Price & Analysis

0 Followers

38I Stock Chart & Stats

CHF 9.60CHF 0.00(0.00%)
At close: 5:30 PM GMT+1
CHF9CHF9.5CHF10Jul 27Aug 14Sep 8Oct 2Oct 19
Day’s Range
CHF 9.60 - CHF 9.60
52-Week Range
CHF 8.59 - CHF 11.22
Previous Close
CHF 9.60
Volume
N/A
Average Volume (3M)
17
Market Cap
CHF 1.12B
Enterprise Value
CHF 1.45B
Total Cash (Recent Filing)
CHF 474.11M
Total Debt (Recent Filing)
CHF 230.14M
Price to Earnings (P/E)
―
Beta
0.87
Next Earnings
Feb 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Phase III Efficacy

The strong Phase III efficacy profile supports the potential for lonvo-z to deliver meaningful clinical benefits in hereditary angioedema. Durable attack reduction and freedom from ongoing therapy could differentiate a one-time treatment and strengthen Intellia’s commercial position if approval is secured.

Regulatory Momentum

BLA acceptance and Priority Review provide a defined regulatory pathway and improve visibility around a potential commercial transition. The absence of a currently planned advisory committee may reduce one source of review complexity, supporting focused launch preparation over the next several months.

Funding Runway

Substantial liquidity and a stated runway into at least 2028 give Intellia time to complete late-stage development, pursue regulatory milestones, and prepare for a potential launch without immediate dependence on product revenue. This supports strategic flexibility while programs advance.

Bears Say

Persistent Cash Burn

Large, recurring cash outflows show that Intellia’s development and commercialization activities are consuming substantial resources before product sales begin. Continued losses increase reliance on liquidity, financing, or milestone proceeds and could constrain investment choices if programs take longer to advance.

Nex-z Safety Risk

The nex-z liver enzyme signal creates a material clinical and regulatory execution risk for a key pipeline program. Monitoring, mitigation, and regulatory engagement may add complexity to development, while safety concerns could affect enrollment, treatment adoption, and the program’s eventual commercial opportunity.

Shrinking Collaboration Revenue

The sharp decline in collaboration revenue weakens a historically important funding source for this clinical-stage company. Lower partner-derived income increases the gap between operating needs and internally generated revenue, leaving Intellia more dependent on financing and future clinical or commercial milestones.

Intellia Therapeutics News

38I FAQ

What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was CHF8.59 and its highest was CHF11.22 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is CHF1.12B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 96 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Nov 05, 2026. The company reported -CHF0.76 earnings per share for the quarter, missing the consensus estimate of -CHF0.666 by -CHF0.094.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -0.66.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 140,358,500 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -CHF0.76 in its last earnings report, missing expectations of -CHF0.666. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Hedge funds hold Intellia Therapeutics shares: the largest hedge-fund position in Intellia Therapeutics is 762,339,366 shares, and hedge funds increased their holdings by 8.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology